+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

United States Vaccine Market Report and Forecast 2024-2032

  • PDF Icon

    Report

  • 160 Pages
  • December 2023
  • Region: United States
  • Expert Market Research
  • ID: 5926360
United States Vaccine Market Report and Forecast 2024-2032

Market Outlook

According to the report the United States vaccine market is projected to grow at a CAGR of 9.8% between 2024 and 2032 to reach a value of about USD 32.87 billion by 2032. Aided by the technological advancements, an increasing focus on preventive healthcare, and a heightened awareness of infectious diseases, the market is expected to grow significantly by 2032.

Vaccines play a crucial role in public health, offering protection against various infectious diseases. In the United States, the vaccine market encompasses a broad range of products, including vaccines for influenza, pneumococcal disease, human papillomavirus (HPV), and a growing portfolio of vaccines for emerging infectious diseases. The demand for these vaccines is driven by a combination of government initiatives, public health campaigns, and a general increase in health consciousness among the populace.

The United States vaccine market outlook is being influenced by the well-established paediatric vaccination program. The routine immunisation schedule recommended by the Centres for Disease Control and Prevention (CDC) has ensured a steady demand for vaccines among children. The adult vaccine segment, though smaller, is also experiencing growth due to the increasing adoption of vaccines for shingles, pneumococcal disease, and HPV among others.

The market is also witnessing an expanding role of public-private partnerships and government funding in vaccine development and distribution. According to the United States vaccine market analysis, these collaborations are crucial in addressing public health needs, especially in the context of emerging infectious diseases and pandemic preparedness. The government's involvement in vaccine procurement and distribution, along with initiatives to ensure vaccine equity and accessibility, is a significant factor driving market growth.

Moreover, there is an increasing need for educational campaigns to address vaccine hesitancy, opening avenues for public health initiatives and collaborations which in turn is boosting the United States vaccine market demand. Moreover, advancements in vaccine storage and delivery systems, such as portable cold storage solutions, offer opportunities for innovation in the logistics and supply chain aspects of the market.

Another opportunity lies in the development of combination vaccines, which can protect against multiple diseases with a single shot. These vaccines are particularly appealing in paediatric immunisation, offering convenience and improved compliance. Additionally, the growing interest in personalised vaccines, tailored to individual genetic profiles, presents a frontier for innovation and market expansion.

Market Segmentation

The market can be divided based on technology, indication, end use, and region.

Market Breakup by Technology

  • Recombinant and Conjugate Vaccine
  • Inactivated Vaccines
  • Live Attenuated Vaccines
  • Toxoid Vaccines
  • Others

Market Breakup by Indication

  • Pneumococcal Disease
  • Influenza
  • Human Papilloma Virus
  • Meningococcal Disease
  • Rotavirus
  • Varicella, Measles, Mumps, and Rubella
  • Diphtheria, Pertussis, and Tetanus (DPT)
  • Polio
  • Hepatitis
  • Others

Market Breakup by End Use

  • Paediatric Vaccine
  • Adult Vaccine
  • Travellers Vaccine

Market Breakup by Region

  • New England
  • Mideast
  • Great Lakes
  • Plains
  • Southeast
  • Southwest
  • Rocky Mountain
  • Far West

Competitive Landscape

The report looks into the market shares, plant turnarounds, capacities, investments, and mergers and acquisitions, among other major developments, of the leading companies operating in the United States vaccine market. Some of the major players explored in the report are as follows:
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • AstraZeneca plc
  • Johnson & Johnson Services, Inc.
  • Others

Table of Contents

1 Preface2 Report Coverage - Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Snapshot
6.1 United States
7 Opportunities and Challenges in the Market
8 United States Vaccine Market Analysis
8.1 Key Industry Highlights
8.2 United States Vaccine Historical Market (2018-2023)
8.3 United States Vaccine Market Forecast (2024-2032)
8.4 United States Vaccine Market by Technology
8.4.1 Recombinant and Conjugate Vaccine
8.4.1.1 Historical Trend (2018-2023)
8.4.1.2 Forecast Trend (2024-2032)
8.4.2 Inactivated Vaccines
8.4.2.1 Historical Trend (2018-2023)
8.4.2.2 Forecast Trend (2024-2032)
8.4.3 Live Attenuated Vaccines
8.4.3.1 Historical Trend (2018-2023)
8.4.3.2 Forecast Trend (2024-2032)
8.4.4 Toxoid Vaccines
8.4.4.1 Historical Trend (2018-2023)
8.4.4.2 Forecast Trend (2024-2032)
8.4.5 Others
8.5 United States Vaccine Market by Indication
8.5.1 Pneumococcal Disease
8.5.1.1 Historical Trend (2018-2023)
8.5.1.2 Forecast Trend (2024-2032)
8.5.2 Influenza
8.5.2.1 Historical Trend (2018-2023)
8.5.2.2 Forecast Trend (2024-2032)
8.5.3 Human Papilloma Virus
8.5.3.1 Historical Trend (2018-2023)
8.5.3.2 Forecast Trend (2024-2032)
8.5.4 Meningococcal Disease
8.5.4.1 Historical Trend (2018-2023)
8.5.4.2 Forecast Trend (2024-2032)
8.5.5 Rotavirus
8.5.5.1 Historical Trend (2018-2023)
8.5.5.2 Forecast Trend (2024-2032)
8.5.6 Varicella, Measles, Mumps, and Rubella
8.5.6.1 Historical Trend (2018-2023)
8.5.6.2 Forecast Trend (2024-2032)
8.5.7 Diphtheria, Pertussis, and Tetanus (DPT)
8.5.7.1 Historical Trend (2018-2023)
8.5.7.2 Forecast Trend (2024-2032)
8.5.8 Polio
8.5.8.1 Historical Trend (2018-2023)
8.5.8.2 Forecast Trend (2024-2032)
8.5.9 Hepatitis
8.5.9.1 Historical Trend (2018-2023)
8.5.9.2 Forecast Trend (2024-2032)
8.5.10 Others
8.6 United States Vaccine Market by End Use
8.6.1 Paediatric Vaccine
8.6.1.1 Historical Trend (2018-2023)
8.6.1.2 Forecast Trend (2024-2032)
8.6.2 Adult Vaccine
8.6.2.1 Historical Trend (2018-2023)
8.6.2.2 Forecast Trend (2024-2032)
8.6.3 Travellers Vaccine
8.6.3.1 Historical Trend (2018-2023)
8.6.3.2 Forecast Trend (2024-2032)
8.7 United States Vaccine Market by Region
8.7.1 New England
8.7.2 Mideast
8.7.3 Great Lakes
8.7.4 Plains
8.7.5 Southeast
8.7.6 Southwest
8.7.7 Rocky Mountain
8.7.8 Far West
9 Regional Analysis
9.1 New England
9.1.1 Historical Trend (2018-2023)
9.1.2 Forecast Trend (2024-2032)
9.2 Mideast
9.2.1 Historical Trend (2018-2023)
9.2.2 Forecast Trend (2024-2032)
9.3 Great Lakes
9.3.1 Historical Trend (2018-2023)
9.3.2 Forecast Trend (2024-2032)
9.4 Plains
9.4.1 Historical Trend (2018-2023)
9.4.2 Forecast Trend (2024-2032)
9.5 Southeast
9.5.1 Historical Trend (2018-2023)
9.5.2 Forecast Trend (2024-2032)
9.6 Southwest
9.6.1 Historical Trend (2018-2023)
9.6.2 Forecast Trend (2024-2032)
9.7 Rocky Mountain
9.7.1 Historical Trend (2018-2023)
9.7.2 Forecast Trend (2024-2032)
9.8 Far West
9.8.1 Historical Trend (2018-2023)
9.8.2 Forecast Trend (2024-2032)
10 Market Dynamics
10.1 SWOT Analysis
10.1.1 Strengths
10.1.2 Weaknesses
10.1.3 Opportunities
10.1.4 Threats
10.2 Porter’s Five Forces Analysis
10.2.1 Supplier’s Power
10.2.2 Buyer’s Power
10.2.3 Threat of New Entrants
10.2.4 Degree of Rivalry
10.2.5 Threat of Substitutes
10.3 Key Indicators for Demand
10.4 Key Indicators for Price
11 Value Chain Analysis
12 Competitive Landscape
12.1 Market Structure
12.2 Company Profiles
12.2.1 GlaxoSmithKline plc
12.2.1.1 Company Overview
12.2.1.2 Product Portfolio
12.2.1.3 Demographic Reach and Achievements
12.2.1.4 Certifications
12.2.2 Merck & Co., Inc.
12.2.2.1 Company Overview
12.2.2.2 Product Portfolio
12.2.2.3 Demographic Reach and Achievements
12.2.2.4 Certifications
12.2.3 Novartis AG
12.2.3.1 Company Overview
12.2.3.2 Product Portfolio
12.2.3.3 Demographic Reach and Achievements
12.2.3.4 Certifications
12.2.4 Pfizer Inc.
12.2.4.1 Company Overview
12.2.4.2 Product Portfolio
12.2.4.3 Demographic Reach and Achievements
12.2.4.4 Certifications
12.2.5 Sanofi
12.2.5.1 Company Overview
12.2.5.2 Product Portfolio
12.2.5.3 Demographic Reach and Achievements
12.2.5.4 Certifications
12.2.6 AstraZeneca plc
12.2.6.1 Company Overview
12.2.6.2 Product Portfolio
12.2.6.3 Demographic Reach and Achievements
12.2.6.4 Certifications
12.2.7 Johnson & Johnson Services, Inc.
12.2.7.1 Company Overview
12.2.7.2 Product Portfolio
12.2.7.3 Demographic Reach and Achievements
12.2.7.4 Certifications
12.2.8 Others
13 Key Trends and Developments in the Market
List of Key Figures and Tables
1. Market: Key Industry Highlights, 2018 and 2032
2. United States Vaccine Historical Market: Breakup by Technology (USD Million), 2018-2023
3. United States Vaccine Market Forecast: Breakup by Technology (USD Million), 2024-2032
4. United States Vaccine Historical Market: Breakup by Indication (USD Million), 2018-2023
5. United States Vaccine Market Forecast: Breakup by Indication (USD Million), 2024-2032
6. United States Vaccine Historical Market: Breakup by End Use (USD Million), 2018-2023
7. United States Vaccine Market Forecast: Breakup by End Use (USD Million), 2024-2032
8. United States Vaccine Historical Market: Breakup by Region (USD Million), 2018-2023
9. United States Vaccine Market Forecast: Breakup by Region (USD Million), 2024-2032
10. United States Vaccine Market Structure

Companies Mentioned

  • GlaxoSmithKline plc
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • AstraZeneca plc
  • Johnson & Johnson Services Inc.

Methodology

Loading
LOADING...